ProCE Banner Activity

C-OPTIMISE: Certolizumab Pegol Therapy Withdrawal in Patients With axSpA Associated With Increased Disease Activity in Patients Without Flares

Slideset Download
Conference Coverage
Even without flare, withdrawal of CZP associated with increased ASDAS, CRP, BASDAI, and fecal calprotectin.

Released: August 03, 2021

Expiration: August 02, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Janssen administered by Scientific Affairs